Avidity Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

• Avidity Biosciences Inc RNA.OQ reported a quarterly adjusted loss of 80 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -79 cents. The mean expectation of ten analysts for the quarter was for a loss of 79 cents per share. Wall Street expected results to range from -90 cents to -63 cents per share.

• Revenue rose 35.6% to $2.97 million from a year ago; analysts expected $1.53 million.

• Avidity Biosciences Inc's reported EPS for the quarter was a loss of 80 cents​.

• The company reported a quarterly loss of $102.26 million.

• Avidity Biosciences Inc shares had risen by 2.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Avidity Biosciences Inc is $65.00

This summary was machine generated from LSEG data February 27 at 10:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)